Rion
Maureen Merrifield has a diverse work experience spanning over 20 years. Maureen is currently serving as the Chief Regulatory Officer at Rion, a position they have held since May 2020. Prior to this, they were the Vice President of Clinical and Regulatory Affairs at Pharmatech Associates from May 2019 to May 2020. Maureen was responsible for overseeing and managing the regulatory affairs division of the company, including nonclinical, clinical, and CMC regulatory strategies, submissions, and management.
Before joining Pharmatech Associates, Merrifield worked as the Director of Regulatory and Strategic Development at Clinipace Worldwide from June 2016 to May 2019. Maureen also held roles as the Director of Regulatory Affairs at Bellicum Pharmaceuticals from August 2015 to February 2016, and as a Regulatory Affairs & Project Manager at the Sabin Vaccine Institute from September 2013 to August 2015.
Merrifield gained valuable industry experience at pharmaceutical companies such as Sanofi, where they served as an Independent Contributor in the Analytical Research and Development Division from September 2010 to August 2013, and GlaxoSmithKline, where they worked as an Analytical Scientist from April 2006 to September 2010. Maureen began their career in research as a Graduate Research Scientist at the University of Western Ontario from September 1999 to November 2005, and as an International Research Intern at the Cardiff School of Biosciences in May 1999.
Throughout their career, Merrifield has demonstrated expertise in regulatory affairs, project management, and strategic development.
Maureen Merrifield obtained their Ph.D. in Chemistry from Western University, where they studied from 1999 to 2005. Prior to that, they completed their Bachelor of Science Honors degree in Chemistry at the same institution from 1995 to 1999. Maureen also holds additional certifications as a member of the Regulatory Affairs Professionals Society (RAPS), but the specific month and year of obtaining these certifications are not provided.
This person is not in any offices
Rion
1 followers
Rion is a clinical-stage biotechnology company That develops exosome therapeutics. Purified Exosome ProductTM (PEPTM) from Rion is a potent, useful, and easily available regenerative medicine. Research by Rion and its scientific partners has demonstrated the potential of PEP to repair a variety of injured tissue, including tendons, muscles, andskin. The goal of Rion is to spread the use of clinically effective regenerative medicine throughout the world.